ondansetron has been researched along with Cancer of Gastrointestinal Tract in 5 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron was injected intravenously in a single dose of 4 mg, 8 mg or 12 mg, at 15 minutes before administration of cisplatin." | 6.67 | [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " From the above, Ondansetron injection which showed sufficient anti-emetic effects on acute emesis and delayed emesis induced by a high single dose or lower multiple doses of cisplatin with its once daily intravenous dose given for 3-5 consecutive days, were considered a safe and clinically useful anti-emetic." | 6.67 | [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "For moderately emetogenic chemotherapy, palonosetron (PALO) is reported to provide complete control of chemotherapy-induced nausea and vomiting (CINV) in 69% of patients." | 5.16 | Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study. ( Bekaii-Saab, T; Blazer, M; Efries, D; Griffith, N; Juergens, K; Phillips, G; Reardon, J; Rose, J; Smith, Y; Weatherby, L, 2012) |
| "In order to make an objective evaluation of anti-emetic effect, safety and usefulness of ondansetron injection in nausea and vomiting associated with cancer chemotherapy, we carried out a double-blind placebo controlled comparative study in patients receiving high-single dose (50 mg/m2 or more) of cisplatin." | 5.07 | [Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron was injected intravenously in a single dose of 4 mg, 8 mg or 12 mg, at 15 minutes before administration of cisplatin." | 2.67 | [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " From the above, Ondansetron injection which showed sufficient anti-emetic effects on acute emesis and delayed emesis induced by a high single dose or lower multiple doses of cisplatin with its once daily intravenous dose given for 3-5 consecutive days, were considered a safe and clinically useful anti-emetic." | 2.67 | [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blazer, M | 1 |
| Phillips, G | 1 |
| Reardon, J | 1 |
| Efries, D | 1 |
| Smith, Y | 1 |
| Weatherby, L | 1 |
| Juergens, K | 1 |
| Rose, J | 1 |
| Griffith, N | 1 |
| Bekaii-Saab, T | 1 |
| Hoshino, K | 1 |
| Ono, K | 1 |
| Kimura, O | 1 |
| Kawaguchi, H | 1 |
| Fukui, H | 1 |
| Ikeda, M | 4 |
| Suminaga, M | 3 |
| Furue, H | 3 |
| Taguchi, T | 3 |
| Ota, K | 3 |
| Niitani, H | 3 |
| Tsukagoshi, S | 3 |
| Ariyoshi, Y | 3 |
| Ohta, J | 3 |
| Akasaka, Y | 3 |
4 trials available for ondansetron and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidi | 2012 |
[Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].
Topics: Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Gastrointestinal Neoplasm | 1992 |
[Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis].
Topics: Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Gastrointestina | 1992 |
[Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Gastrointestinal Neoplasms; Humans; Injections, | 1992 |
1 other study available for ondansetron and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
[Usefulness of continuous venous daily chemotherapy of 5-fluorouracil and low-dose cisplatin for patients undergoing noncurative surgery].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 1997 |